HALO

$0.00

(

0.00%

)
Quote details

stock

Halozyme Therapeutics Inc

NASDAQ | HALO

73.75

USD

$0.00

(

0.00%

)

At Close (As of Sep 26, 2025)

$8.85B

Market Cap

16.93

P/E Ratio

4.37

EPS

$79.50

52 Week High

$42.01

52 Week Low

HEALTHCARE

Sector

HALO Chart

Recent Chart
Price Action

HALO Technicals

Tags:

HALO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $856M
Total Revenue $1B
Cost Of Revenue $159M
Costof Goods And Services Sold $159M
Operating Income $551M
Selling General And Administrative $154M
Research And Development $79M
Operating Expenses $304M
Investment Income Net -
Net Interest Income -$18M
Interest Income -
Interest Expense $18M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $81M
Income Before Tax $557M
Income Tax Expense $113M
Interest And Debt Expense -
Net Income From Continuing Operations $444M
Comprehensive Income Net Of Tax -
Ebit $575M
Ebitda $657M
Net Income $444M

Revenue & Profitability

Earnings Performance

HALO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $2.1B
Total Current Assets $1.1B
Cash And Cash Equivalents At Carrying Value $116M
Cash And Short Term Investments $116M
Inventory $142M
Current Net Receivables $308M
Total Non Current Assets $978M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $402M
Intangible Assets Excluding Goodwill $402M
Goodwill $417M
Investments -
Long Term Investments -
Short Term Investments $480M
Other Current Assets $39M
Other Non Current Assets -
Total Liabilities $1.7B
Total Current Liabilities $139M
Current Accounts Payable $10M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $1.6B
Capital Lease Obligations -
Long Term Debt $1.5B
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.5B
Other Current Liabilities $129M
Other Non Current Liabilities $55M
Total Shareholder Equity $364M
Treasury Stock -
Retained Earnings $360M
Common Stock $123K
Common Stock Shares Outstanding $129M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $479M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $81M
Capital Expenditures $11M
Change In Receivables -
Change In Inventory -$67M
Profit Loss -
Cashflow From Investment -$263M
Cashflow From Financing -$219M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$250M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $444M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $856M
Total Revenue $1B
Cost Of Revenue $159M
Costof Goods And Services Sold $159M
Operating Income $551M
Selling General And Administrative $154M
Research And Development $79M
Operating Expenses $304M
Investment Income Net -
Net Interest Income -$18M
Interest Income -
Interest Expense $18M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $81M
Income Before Tax $557M
Income Tax Expense $113M
Interest And Debt Expense -
Net Income From Continuing Operations $444M
Comprehensive Income Net Of Tax -
Ebit $575M
Ebitda $657M
Net Income $444M

HALO News

HALO Profile

Halozyme Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Halozyme Therapeutics, Inc. is a leading biopharmaceutical technology company based in San Diego, California, specializing in innovative drug delivery solutions that enhance the efficacy of existing therapies. With a global presence across the United States, Europe, and Asia, Halozyme leverages its proprietary ENHANZE® technology to develop subcutaneous formulations for various indications, improving patient experience and compliance. The company collaborates with major pharmaceutical partners to expand its therapeutic portfolio, positioning itself as a pivotal player in the evolving landscape of biotechnology and drug administration.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.